Verification evidence is still being completed.
PDF / print export
Rezon Bio
Gdansk / Warsaw, Poland
- Verified lead
- Adriana Kiedzierska-Mencfeld
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- Chief Executive Officer
- 2026 technical specialization
- Biosimilars and Mammalian Cell Culture
- Review cycle
- May 2026
- Full address
- ul. Trzy Lipy 3, 80-172 Gdańsk, Poland
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official Rezon Bio company and leadership surface confirming Adriana Kiedzierska-Mencfeld as CEO.
- Editorial note
- Rezon Bio transition platform combining biosimilar development, mammalian cell culture, and CDMO execution across the Gdańsk-Warsaw footprint.
Biosimilars and Mammalian Cell Culture
Commercial Biologics Platform, GMP Manufacturing
Rezon Bio transition platform combining biosimilar development, mammalian cell culture, and CDMO execution across the Gdańsk-Warsaw footprint.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Rezon Bio transition platform combining biosimilar development, mammalian cell culture, and CDMO execution across the Gdańsk-Warsaw footprint.
- Lead
- Adriana Kiedzierska-Mencfeld (verified ↗)
- Address
- ul. Trzy Lipy 3, 80-172 Gdańsk, Poland (source ↗)
- Compliance
- GMP Manufacturing
- Last reviewed
- 14 Mar 2026 (3mo ago)
- Scale
- Commercial biologics CDMO
- Capabilities
- Biosimilar Development · Mammalian Cell Culture · Bioprocess Scale-up
- Founded
- 2013
- Headcount
- 201-500
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED MARCH 2026
Adriana Kiedzierska-Mencfeld
Chief Executive Officer
Full addressul. Trzy Lipy 3, 80-172 Gdańsk, Poland
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Physical site source
Official Rezon Bio legal and privacy notices listing the registered office at ul. Trzy Lipy 3 in Gdańsk.
Open sourceCommercial biologics CDMO
Gdansk / Warsaw, Poland. Biosimilars and Mammalian Cell Culture. Review completed on 14 Mar 2026.
Polish and EU pharmaceutical oversight
Commercial Biologics Platform, GMP Manufacturing
Biosimilars and Mammalian Cell Culture
Rezon Bio transition platform combining biosimilar development, mammalian cell culture, and CDMO execution across the Gdańsk-Warsaw footprint.
Editorial note
Former Polpharma Biologics CDMO node now presented under the Rezon Bio brand.
Current review cycleMarch 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Biosimilar Development
Mammalian Cell Culture
Bioprocess Scale-up
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Equipment detail not disclosed in the current record.
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- VERIFIED ACTIVE 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
14 Mar 2026: Executive identity confirmed via official management disclosure.
14 Mar 2026: Trust review remains in progress.
FAQ
Frequently asked questions
- Where is Rezon Bio located?
- Rezon Bio operates from ul. Trzy Lipy 3, 80-172 Gdańsk, Poland, Gdansk / Warsaw, Poland.
- Who runs Rezon Bio?
- Rezon Bio is led by Adriana Kiedzierska-Mencfeld, Chief Executive Officer. Verified 14 Mar 2026.
- What certifications does Rezon Bio hold?
- Rezon Bio is documented under GMP Manufacturing.
- What does Rezon Bio do?
- Rezon Bio transition platform combining biosimilar development, mammalian cell culture, and CDMO execution across the Gdańsk-Warsaw footprint. Core capabilities: Biosimilar Development, Mammalian Cell Culture, Bioprocess Scale-up.
Editorial context
Related technical briefs
Briefs that name Gdansk / Warsaw as a covered market or city.